Monday 7 April marks World Health Day, a day organised by the World Health Organization (WHO) to highlight a particular global health issue. This year, it aims to kick off a year-long campaign on maternal and newborn health.

Maternal, newborn, and child health is a major global health priority, and yet in many parts of the world there are still far too many preventable deaths among mothers and young children. The World Health Organization (WHO) estimates that close to 300,000 women die during and following childbirth each year. Around 95% of those deaths occur in low- and middle-income countries, in one of the starkest demonstrations of global health inequities. Postpartum haemorrhage alone accounts for over a quarter of maternal deaths each year, a number that emphasises the urgent need for evidence-based interventions.

Maternal, newborn, and child health: one of the four pillars

At Cochrane, our vision is a healthier world for everyone where health and care decisions are informed by high-quality evidence.

Cochrane has a long and proud history of advancing maternal, newborn, and child health. Much of our early work focused on evaluating evidence-based strategies to prevent illness and death among expectant mothers and babies, shaping international guidelines on labour induction and postnatal care. We have also contributed to landmark reviews, including one on the benefits of steroid injections for women at risk of preterm birth, research that even inspired the Cochrane logo.

With maternal, child and newborn health being one of the strategic pillars in our scientific strategy, we remain committed to improving the health and wellbeing of mothers and children worldwide and tackling the vast health equity gap between different populations. We will assess strategies aimed at preventing illnesses and deaths related to pregnancy and childbirth, enhance prevention and treatment for diseases in babies and children, and help improve sexual health and fertility services.

What are we doing?

Cochrane has a strong track record in maternal, newborn, and child health, with over 220 reviews informing WHO recommendations in this area.

Last year we collaborated with the WHO on a suite of 14 rapid reviews to improve the prevention and treatment of postpartum haemorrhage. This work is part of WHO’s four-point plan to accelerate progress toward the Sustainable Development Goal of reducing maternal mortality to 70 deaths per 100,000 live births by 2030 (SDG 3.1). By fast-tracking evidence synthesis, Cochrane’s reviews will inform updated WHO guidelines, influencing maternal healthcare policies worldwide.

Beyond postpartum haemorrhage, Cochrane is evaluating interventions for maternal infections, pre-eclampsia prevention through calcium supplementation, diabetes management during pregnancy, and clinical management of caesarean sections. These areas are critical for improving maternal health outcomes, particularly in low-resource settings.

“High-quality evidence is essential for improving maternal and newborn health worldwide. Through Cochrane’s scientific strategy, we address critical global health needs and pressing research questions,” explains Roses Parker, Commissioning Editor at Cochrane. “We collaborate with decision-makers to ensure they have access to the best available evidence for policy and practice. Currently, we are focusing on a suite of reviews on diagnosing and managing gestational diabetes and partnering with Cochrane India to develop an evidence gap map to guide future work on neonatal mortality.” 

The need for evidence-based policy

The leading causes of maternal, neonatal, and child mortality are largely known, preventable, and treatable through strategic, population-based healthcare policies. Despite this, inequalities due to income, education, gender, race and/or ethnicity limit access to care, further marginalising these vulnerable populations. Recognising this disproportionate burden in LMICs, Cochrane is prioritising capacity building and evidence co-production in these regions.

Cochrane remains committed to working alongside the WHO, governments, and health systems to turn high-quality research into life-saving policies. Strengthening maternal, newborn, and child health systems through evidence-based interventions is critical to achieving global health goals and ensuring health for all.

• Read more about World Health Day 2025
• Find out more about our scientific strategy

 

Monday, April 7, 2025

Monday 7 April marks World Health Day, a day organised by the World Health Organization (WHO) to highlight a particular global health issue. This year, it aims to kick off a year-long campaign on maternal and newborn health.

Maternal, newborn, and child health is a major global health priority, and yet in many parts of the world there are still far too many preventable deaths among mothers and young children. The World Health Organization (WHO) estimates that close to 300,000 women die during and following childbirth each year. Around 95% of those deaths occur in low- and middle-income countries, in one of the starkest demonstrations of global health inequities. Postpartum haemorrhage alone accounts for over a quarter of maternal deaths each year, a number that emphasises the urgent need for evidence-based interventions.

Maternal, newborn, and child health: one of the four pillars

At Cochrane, our vision is a healthier world for everyone where health and care decisions are informed by high-quality evidence.

Cochrane has a long and proud history of advancing maternal, newborn, and child health. Much of our early work focused on evaluating evidence-based strategies to prevent illness and death among expectant mothers and babies, shaping international guidelines on labour induction and postnatal care. We have also contributed to landmark reviews, including one on the benefits of steroid injections for women at risk of preterm birth, research that even inspired the Cochrane logo.

With maternal, child and newborn health being one of the strategic pillars in our scientific strategy, we remain committed to improving the health and wellbeing of mothers and children worldwide and tackling the vast health equity gap between different populations. We will assess strategies aimed at preventing illnesses and deaths related to pregnancy and childbirth, enhance prevention and treatment for diseases in babies and children, and help improve sexual health and fertility services.

What are we doing?

Cochrane has a strong track record in maternal, newborn, and child health, with over 220 reviews informing WHO recommendations in this area.

Last year we collaborated with the WHO on a suite of 14 rapid reviews to improve the prevention and treatment of postpartum haemorrhage. This work is part of WHO’s four-point plan to accelerate progress toward the Sustainable Development Goal of reducing maternal mortality to 70 deaths per 100,000 live births by 2030 (SDG 3.1). By fast-tracking evidence synthesis, Cochrane’s reviews will inform updated WHO guidelines, influencing maternal healthcare policies worldwide.

Beyond postpartum haemorrhage, Cochrane is evaluating interventions for maternal infections, pre-eclampsia prevention through calcium supplementation, diabetes management during pregnancy, and clinical management of caesarean sections. These areas are critical for improving maternal health outcomes, particularly in low-resource settings.

“High-quality evidence is essential for improving maternal and newborn health worldwide. Through Cochrane’s scientific strategy, we address critical global health needs and pressing research questions,” explains Roses Parker, Commissioning Editor at Cochrane. “We collaborate with decision-makers to ensure they have access to the best available evidence for policy and practice. Currently, we are focusing on a suite of reviews on diagnosing and managing gestational diabetes and partnering with Cochrane India to develop an evidence gap map to guide future work on neonatal mortality.” 

The need for evidence-based policy

The leading causes of maternal, neonatal, and child mortality are largely known, preventable, and treatable through strategic, population-based healthcare policies. Despite this, inequalities due to income, education, gender, race and/or ethnicity limit access to care, further marginalising these vulnerable populations. Recognising this disproportionate burden in LMICs, Cochrane is prioritising capacity building and evidence co-production in these regions.

Cochrane remains committed to working alongside the WHO, governments, and health systems to turn high-quality research into life-saving policies. Strengthening maternal, newborn, and child health systems through evidence-based interventions is critical to achieving global health goals and ensuring health for all.

• Read more about World Health Day 2025
• Find out more about our scientific strategy

 

Monday, April 7, 2025

Title: Subscription Renewals Officer
Specifications: Permanent – Full time or Part Time (minimum 22.5 hours)
Salary: £35,000 per annum full time 
Location: (Remote) resident in the UK, Germany or Denmark. 
Directorate: Development and External Relations Directorate
Closing date: 15 April, 2025

The Subscription Renewals Officer role will work closely with the Business Development Manager to grow the organisation’s commercial services income. As SRO, you will be responsible for supporting customer satisfaction and maximising customer lifetime value through successful contract renewals.

Joining our team means becoming part of a mission to enhance global health through reliable, evidence-based practices. You'll collaborate with dedicated professionals and partners worldwide to ensure health decisions are informed by the best available data. Our core values — collaboration, relevance, integrity, and quality — guide all our actions. By joining us, you'll contribute to making a significant impact on health outcomes globally.

Don’t have every single qualification? We know that some people are less likely to apply for a job unless they are a perfect match. At Cochrane, we’re not looking for “perfect matches.” We’re looking to welcome people to our diverse, inclusive, and passionate workplace. So, if you’re excited about this role but don’t have every single qualification, we encourage you to apply anyway. Whether it’s this role or another one, you may be just the right candidate.

Cochrane welcomes applications from a wide range of perspectives, experiences, locations and backgrounds; diversity, equity and inclusion are key to our values.

How to apply

• For further information on the role and how to apply, please click here.
• The deadline to receive your application is 15 April, 2025.  We reserve the right to close this vacancy early if we receive sufficient applications for the role. Therefore, if you are interested, please submit your application as early as possible.
• The supporting statement should indicate why you are applying for the post, and how far you meet the requirements, using specific examples.
• Interviews will be held on w/c 28 April 2025.
• Read our Recruitment Privacy Statement.
• Read our Candidate pack for more information on the hiring process and staff benefits.

 

 

Wednesday, April 2, 2025 Category: Jobs

Title: Subscription Renewals Officer
Specifications: Permanent – Full time or Part Time (minimum 22.5 hours)
Salary: £35,000 per annum full time 
Location: (Remote) resident in the UK, Germany or Denmark. 
Directorate: Development and External Relations Directorate
Closing date: 15 April, 2025

The Subscription Renewals Officer role will work closely with the Business Development Manager to grow the organisation’s commercial services income. As SRO, you will be responsible for supporting customer satisfaction and maximising customer lifetime value through successful contract renewals.

Joining our team means becoming part of a mission to enhance global health through reliable, evidence-based practices. You'll collaborate with dedicated professionals and partners worldwide to ensure health decisions are informed by the best available data. Our core values — collaboration, relevance, integrity, and quality — guide all our actions. By joining us, you'll contribute to making a significant impact on health outcomes globally.

Don’t have every single qualification? We know that some people are less likely to apply for a job unless they are a perfect match. At Cochrane, we’re not looking for “perfect matches.” We’re looking to welcome people to our diverse, inclusive, and passionate workplace. So, if you’re excited about this role but don’t have every single qualification, we encourage you to apply anyway. Whether it’s this role or another one, you may be just the right candidate.

Cochrane welcomes applications from a wide range of perspectives, experiences, locations and backgrounds; diversity, equity and inclusion are key to our values.

How to apply

• For further information on the role and how to apply, please click here.
• The deadline to receive your application is 15 April, 2025.  We reserve the right to close this vacancy early if we receive sufficient applications for the role. Therefore, if you are interested, please submit your application as early as possible.
• The supporting statement should indicate why you are applying for the post, and how far you meet the requirements, using specific examples.
• Interviews will be held on w/c 28 April 2025.
• Read our Recruitment Privacy Statement.
• Read our Candidate pack for more information on the hiring process and staff benefits.

 

 

Wednesday, April 2, 2025 Category: Jobs

How accurate are Truenat assays for detecting pulmonary tuberculosis and rifampicin resistance?

On World TB Day, we highlight findings from a new review assessing the accuracy of Truenat assays for detecting pulmonary tuberculosis (TB) and rifampicin resistance in adults and adolescents.

TB remains a global health threat, with 10.8 million cases and 1.25 million deaths in 2023, according to the World Health Organization. The number of people with tuberculosis keeps increasing. Both false-positive results and false-negative results have a severe impact on individuals tested. It is crucial that there is early and accurate diagnosis to prevent the spread of TB and ensure timely treatment. 

This review included six studies with over 4000 participants, comparing Truenat assays to the WHO-recommended Xpert Ultra test. While Truenat MTB Plus showed promise, further research is needed to refine diagnostic tools, particularly for drug-resistant TB.

Key findings:

• Truenat MTB Plus was more accurate than Truenat MTB for detecting TB. However, Truenat MTB misidentified many people as having TB when they did not, raising concerns. 
•  Xpert Ultra was found to be more accurate than Truenat MTB.
• Evidence on Truenat’s accuracy for detecting rifampicin resistance was limited.

Read the full review here: https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015543.pub2/full

Thursday, March 20, 2025

How accurate are Truenat assays for detecting pulmonary tuberculosis and rifampicin resistance?

On World TB Day, we highlight findings from a new review assessing the accuracy of Truenat assays for detecting pulmonary tuberculosis (TB) and rifampicin resistance in adults and adolescents.

TB remains a global health threat, with 10.8 million cases and 1.25 million deaths in 2023, according to the World Health Organization. The number of people with tuberculosis keeps increasing. Both false-positive results and false-negative results have a severe impact on individuals tested. It is crucial that there is early and accurate diagnosis to prevent the spread of TB and ensure timely treatment. 

This review included six studies with over 4000 participants, comparing Truenat assays to the WHO-recommended Xpert Ultra test. While Truenat MTB Plus showed promise, further research is needed to refine diagnostic tools, particularly for drug-resistant TB.

Key findings:

• Truenat MTB Plus was more accurate than Truenat MTB for detecting TB. However, Truenat MTB misidentified many people as having TB when they did not, raising concerns. 
•  Xpert Ultra was found to be more accurate than Truenat MTB.
• Evidence on Truenat’s accuracy for detecting rifampicin resistance was limited.

Read the full review here: https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015543.pub2/full

Thursday, March 20, 2025

Catherine Spencer OBE, who served as the Cochrane Collaboration’s Chief Executive Officer since 2022, has decided to step down from the role.

Catherine has led Cochrane through transformational change, developing a new strategy for a more evidence-informed world and ensuring the organization is well-placed to deliver it. She has helped to cement Cochrane’s reputation as a world-leading source of trustworthy evidence and expand the charity’s reach and impact around the world.

“I have been so fortunate to work with incredibly talented and loyal colleagues, Board Members and community members,” said Catherine. “All have worked hard to ensure that Cochrane has a great future and is a wonderful environment in which to work and grow. I wish all the team well as they focus on the continued success of Cochrane.”

The Governing Board has appointed Dr Karla Soares-Weiser as Acting CEO while they prepare to recruit the next CEO. Cochrane’s Deputy Editor-in-Chief, Toby Lasserson, will serve as Acting Editor-in-Chief.

Dr Susan Phillips, Chair of Cochrane’s Governing Board, said:

“The Governing Board would like to thank Catherine for her valued contribution to Cochrane and Cochrane community. In her time as CEO, she has ensured that the organization has a warm and collaborative culture that fosters innovation and trust.

“We wish to acknowledge the important contribution Catherine has made towards stabilizing Cochrane’s operations, developing the 2024-2027 Organizational Strategy, supporting Cochrane’s transition to a centralized editorial service and implementing the Roadmap to Open Access.

“Consequently, Cochrane is in a strong position, and we anticipate building on these achievements. Our priorities will be to strengthen Cochrane’s evidence synthesis model, including our use of AI tools, and to develop business models and methods which make us more responsive to funders’ needs.”

Preparations to recruit the next CEO will be led by Cochrane’s Governing Board.

Wednesday, March 12, 2025

Catherine Spencer OBE, who served as the Cochrane Collaboration’s Chief Executive Officer since 2022, has decided to step down from the role.

Catherine has led Cochrane through transformational change, developing a new strategy for a more evidence-informed world and ensuring the organization is well-placed to deliver it. She has helped to cement Cochrane’s reputation as a world-leading source of trustworthy evidence and expand the charity’s reach and impact around the world.

“I have been so fortunate to work with incredibly talented and loyal colleagues, Board Members and community members,” said Catherine. “All have worked hard to ensure that Cochrane has a great future and is a wonderful environment in which to work and grow. I wish all the team well as they focus on the continued success of Cochrane.”

The Governing Board has appointed Dr Karla Soares-Weiser as Acting CEO while they prepare to recruit the next CEO. Cochrane’s Deputy Editor-in-Chief, Toby Lasserson, will serve as Acting Editor-in-Chief.

Dr Susan Phillips, Chair of Cochrane’s Governing Board, said:

“The Governing Board would like to thank Catherine for her valued contribution to Cochrane and Cochrane community. In her time as CEO, she has ensured that the organization has a warm and collaborative culture that fosters innovation and trust.

“We wish to acknowledge the important contribution Catherine has made towards stabilizing Cochrane’s operations, developing the 2024-2027 Organizational Strategy, supporting Cochrane’s transition to a centralized editorial service and implementing the Roadmap to Open Access.

“Consequently, Cochrane is in a strong position, and we anticipate building on these achievements. Our priorities will be to strengthen Cochrane’s evidence synthesis model, including our use of AI tools, and to develop business models and methods which make us more responsive to funders’ needs.”

Preparations to recruit the next CEO will be led by Cochrane’s Governing Board.

Wednesday, March 12, 2025

March 2025 marks the third anniversary of Cochrane’s commitment to Public Involvement in Health and Social Care Research, a pledge launched in 2022. This commitment underscores Cochrane's ongoing efforts  to enhance its practice of public involvement, ensuring that the voices of the users of our evidence are at the heart of health and social care evidence.

Excellent public involvement is an essential part of health and social care research and improves the quality and impact of research. Excellent public involvement is inclusive, values all contributions, ensures people have a meaningful say in what happens, and influences outcomes, as set out in the UK Standards for Public Involvement.

Cochrane is proud to be one of the thirty two organizations in partnership on this important initiative. Together, partners connect during quarterly Learning and Sharing meetings to share best practices and new developments, amplifying excellent public involvement and maximising resources for optimised efforts and impact.

Reflecting on this milestone, April English, Cochrane’s Consumer Engagement Manager, states: “Our commitment to public involvement is key to advancing health and social care research and demonstrating our value for the invaluable contributions of patients and the public, ultimately improving the quality and impact of research.”

“People have the right to be involved in all health and social care research,” Ana Beatriz Pizarro, member of the Consumer Network Executive, reflects. “People’s lived experiences should be a key driver for health and social care research.”

Key Achievements and Initiatives

Over the past three years, Cochrane has taken significant steps to strengthen public involvement, including:

• Cochrane’s Consumer Network: In 2025, three new members joined the Consumer Network Executive, and as of January 2025, over 2,500 members have joined the Consumer Network. Both, strengthening the community of people interested in high-quality health evidence, and in helping to be a part of producing and sharing evidence.
• Reporting Consumer Involvement: Since 2024, all new Cochrane reviews must report on consumer involvement.
• Consumer Representation on Editorial Board: The Editorial Board is responsible for supporting Cochrane’s Editor in Chief and overseeing the production of Cochrane Reviews and other Cochrane Library content. The Editorial Board includes representation from the Consumer Network.
• Consumer Peer Review of Submitted Cochrane Reviews and Protocols: Recent consumer peer reviews include Electronic cigarettes for smoking cessation, Interventions implemented through sporting organisations for promoting healthy behaviour or improving health outcomes, Prevention of self‐harm and suicide in young people up to the age of 25 in education settings, and Water fluoridation for the prevention of dental caries. 
• The Co-Production Methods Group: Launched in October 2023, this group advances research on co-production methods, shares best practices, and supports learning to help systematic review authors engage meaningfully with healthcare consumers.
• Evidence Essentials:  A free, online learning module co-produced by healthcare consumers, researchers, and Cochrane specialists, helping people understand health evidence and make informed health choices. In 2024, module six was launched on critical appraisal of rapid reviews.
• Learning Live Webinars:  A series of free webinars tailored for different audiences, including review authors and the public, providing guidance on engaging with Cochrane evidence and making research more accessible.

Cochrane’s Framework for Public Involvement

Cochrane’s framework for consumer engagement and involvement focuses on five key elements:

1. Engagement: Strengthening communication, evidence dissemination, recruitment, and learning opportunities for consumers.
2. Co-Production: Increasing consumer involvement in evidence production and governance to align research with user needs.
3. Accessibility: Enhancing health literacy and making Cochrane evidence easier to access and understand.
4. Strategic Partnerships: Collaborating with patient groups and other stakeholders to advance engagement, co-production, and advocacy efforts.
5. Evaluation and Reporting: Establishing key engagement and involvement metrics for evaluating and reporting the impact of Cochrane’s engagement and involvement activity. 
   
   
   

How to Get Involved?

There are many ways to play a part in health and social care research  at Cochrane.

Join Cochrane's Consumer Network, a large and growing community of people across the world. We welcome patients, carers and the public who are interested in getting involved in and sharing high-quality health evidence.

Cochrane Engage and Cochrane Crowd are always looking for volunteers to get involved with research.

• Learn more about Cochrane’s commitment to healthcare consumers
• Contact the Cochrane’s Consumer Engagement Manager or Cochrane’s Consumers Network Executive at consumers@cochrane.org 
  

 

Tuesday, March 11, 2025

March 2025 marks the third anniversary of Cochrane’s commitment to Public Involvement in Health and Social Care Research, a pledge launched in 2022. This commitment underscores Cochrane's ongoing efforts  to enhance its practice of public involvement, ensuring that the voices of the users of our evidence are at the heart of health and social care evidence.

Excellent public involvement is an essential part of health and social care research and improves the quality and impact of research. Excellent public involvement is inclusive, values all contributions, ensures people have a meaningful say in what happens, and influences outcomes, as set out in the UK Standards for Public Involvement.

Cochrane is proud to be one of the thirty two organizations in partnership on this important initiative. Together, partners connect during quarterly Learning and Sharing meetings to share best practices and new developments, amplifying excellent public involvement and maximising resources for optimised efforts and impact.

Reflecting on this milestone, April English, Cochrane’s Consumer Engagement Manager, states: “Our commitment to public involvement is key to advancing health and social care research and demonstrating our value for the invaluable contributions of patients and the public, ultimately improving the quality and impact of research.”

“People have the right to be involved in all health and social care research,” Ana Beatriz Pizarro, member of the Consumer Network Executive, reflects. “People’s lived experiences should be a key driver for health and social care research.”

Key Achievements and Initiatives

Over the past three years, Cochrane has taken significant steps to strengthen public involvement, including:

• Cochrane’s Consumer Network: In 2025, three new members joined the Consumer Network Executive, and as of January 2025, over 2,500 members have joined the Consumer Network. Both, strengthening the community of people interested in high-quality health evidence, and in helping to be a part of producing and sharing evidence.
• Reporting Consumer Involvement: Since 2024, all new Cochrane reviews must report on consumer involvement.
• Consumer Representation on Editorial Board: The Editorial Board is responsible for supporting Cochrane’s Editor in Chief and overseeing the production of Cochrane Reviews and other Cochrane Library content. The Editorial Board includes representation from the Consumer Network.
• Consumer Peer Review of Submitted Cochrane Reviews and Protocols: Recent consumer peer reviews include Electronic cigarettes for smoking cessation, Interventions implemented through sporting organisations for promoting healthy behaviour or improving health outcomes, Prevention of self‐harm and suicide in young people up to the age of 25 in education settings, and Water fluoridation for the prevention of dental caries. 
• The Co-Production Methods Group: Launched in October 2023, this group advances research on co-production methods, shares best practices, and supports learning to help systematic review authors engage meaningfully with healthcare consumers.
• Evidence Essentials:  A free, online learning module co-produced by healthcare consumers, researchers, and Cochrane specialists, helping people understand health evidence and make informed health choices. In 2024, module six was launched on critical appraisal of rapid reviews.
• Learning Live Webinars:  A series of free webinars tailored for different audiences, including review authors and the public, providing guidance on engaging with Cochrane evidence and making research more accessible.

Cochrane’s Framework for Public Involvement

Cochrane’s framework for consumer engagement and involvement focuses on five key elements:

1. Engagement: Strengthening communication, evidence dissemination, recruitment, and learning opportunities for consumers.
2. Co-Production: Increasing consumer involvement in evidence production and governance to align research with user needs.
3. Accessibility: Enhancing health literacy and making Cochrane evidence easier to access and understand.
4. Strategic Partnerships: Collaborating with patient groups and other stakeholders to advance engagement, co-production, and advocacy efforts.
5. Evaluation and Reporting: Establishing key engagement and involvement metrics for evaluating and reporting the impact of Cochrane’s engagement and involvement activity. 
   
   
   

How to Get Involved?

There are many ways to play a part in health and social care research  at Cochrane.

Join Cochrane's Consumer Network, a large and growing community of people across the world. We welcome patients, carers and the public who are interested in getting involved in and sharing high-quality health evidence.

Cochrane Engage and Cochrane Crowd are always looking for volunteers to get involved with research.

• Learn more about Cochrane’s commitment to healthcare consumers
• Contact the Cochrane’s Consumer Engagement Manager or Cochrane’s Consumers Network Executive at consumers@cochrane.org 
  

 

Tuesday, March 11, 2025

Title:  Digital Marketing Manager
Specifications: Permanent – Full Time
Salary: £52,000 per annum
Location: (Remote) resident in the UK, Germany or Denmark. 
Directorate: Development and External Relations Directorate
Closing date: 19 March, 2025

The Digital Marketing Manager is an exciting new role that reflects the strategic importance of digital marketing to Cochrane, an internationally renowned charity providing high-quality health evidence.

You will establish and oversee the organization’s digital marketing function, recruiting and managing a part-time (0.6 FTE) Digital Marketing Officer. Together you will deliver high-quality, targeted digital marketing campaigns that inspire engagement and support from a range of audiences.

This role will oversee both brand marketing for diverse audiences and B2B/B2C marketing aimed primarily at universities and academics. Brand marketing will involve ownership of Cochrane’s social media accounts and oversight of email marketing, working closely with colleagues who manage the CRM (SugarCRM). Commercial marketing will include promoting academic conferences, on-demand training courses, and specialist software (SaaS).

Joining our team means becoming part of a mission to enhance global health through reliable, evidence-based practices. You'll collaborate with dedicated professionals and partners worldwide to ensure health decisions are informed by the best available data. Our core values — collaboration, relevance, integrity, and quality — guide all our actions. By joining us, you'll contribute to making a significant impact on health outcomes globally.

Don’t have every single qualification? We know that some people are less likely to apply for a job unless they are a perfect match. At Cochrane, we’re not looking for “perfect matches.” We’re looking to welcome people to our diverse, inclusive, and passionate workplace. So, if you’re excited about this role but don’t have every single qualification, we encourage you to apply anyway. Whether it’s this role or another one, you may be just the right candidate.

Cochrane welcomes applications from a wide range of perspectives, experiences, locations and backgrounds; diversity, equity and inclusion are key to our values.

How to apply

• For further information on the role and how to apply, please click here.
• The deadline to receive your application is 19 March, 2025. We reserve the right to close this vacancy early if we receive sufficient applications for the role. Therefore, if you are interested, please submit your application as early as possible.
• The supporting statement should indicate why you are applying for the post, and how far you meet the requirements, using specific examples.
• Interviews will be held on w/c 24 March 2025.
• Read our Recruitment Privacy Statement.
• Read our Candidate pack for more information on the hiring process and staff benefits

 

Friday, March 7, 2025 Category: Jobs

Title:  Digital Marketing Manager
Specifications: Permanent – Full Time
Salary: £52,000 per annum
Location: (Remote) resident in the UK, Germany or Denmark. 
Directorate: Development and External Relations Directorate
Closing date: 19 March, 2025

The Digital Marketing Manager is an exciting new role that reflects the strategic importance of digital marketing to Cochrane, an internationally renowned charity providing high-quality health evidence.

You will establish and oversee the organization’s digital marketing function, recruiting and managing a part-time (0.6 FTE) Digital Marketing Officer. Together you will deliver high-quality, targeted digital marketing campaigns that inspire engagement and support from a range of audiences.

This role will oversee both brand marketing for diverse audiences and B2B/B2C marketing aimed primarily at universities and academics. Brand marketing will involve ownership of Cochrane’s social media accounts and oversight of email marketing, working closely with colleagues who manage the CRM (SugarCRM). Commercial marketing will include promoting academic conferences, on-demand training courses, and specialist software (SaaS).

Joining our team means becoming part of a mission to enhance global health through reliable, evidence-based practices. You'll collaborate with dedicated professionals and partners worldwide to ensure health decisions are informed by the best available data. Our core values — collaboration, relevance, integrity, and quality — guide all our actions. By joining us, you'll contribute to making a significant impact on health outcomes globally.

Don’t have every single qualification? We know that some people are less likely to apply for a job unless they are a perfect match. At Cochrane, we’re not looking for “perfect matches.” We’re looking to welcome people to our diverse, inclusive, and passionate workplace. So, if you’re excited about this role but don’t have every single qualification, we encourage you to apply anyway. Whether it’s this role or another one, you may be just the right candidate.

Cochrane welcomes applications from a wide range of perspectives, experiences, locations and backgrounds; diversity, equity and inclusion are key to our values.

How to apply

• For further information on the role and how to apply, please click here.
• The deadline to receive your application is 19 March, 2025. We reserve the right to close this vacancy early if we receive sufficient applications for the role. Therefore, if you are interested, please submit your application as early as possible.
• The supporting statement should indicate why you are applying for the post, and how far you meet the requirements, using specific examples.
• Interviews will be held on w/c 24 March 2025.
• Read our Recruitment Privacy Statement.
• Read our Candidate pack for more information on the hiring process and staff benefits

 

Friday, March 7, 2025 Category: Jobs

A new Cochrane review has found evidence that music-based therapy may benefit people living with dementia, particularly by improving symptoms of depression. 

Dementia is a collective term for progressive degenerative brain syndromes that affect memory, thinking, behaviour and emotion. Alzheimer’s Disease International reported that there were 55 million people with dementia worldwide in 2019, a figure predicted to increase to 139 million by 2050. While some medicines are available, the therapeutic use of music is considered a relatively simple and inexpensive approach that remains accessible even in the later stages of dementia.  

The research team from several institutions in the Netherlands examined evidence from 30 studies involving 1,720 people. The studies investigated the effects of music-based therapeutic interventions on emotional well-being including quality of life, mood disturbance, behavioural problems, social behaviour, and cognition. Most participants were in care homes, with interventions delivered either individually or in group settings. 

The trials were primarily conducted in high-income countries, including Australia, Taiwan, the US, and various European countries.  Almost all the therapies included active elements (such as playing instruments), often combined with receptive elements (such as listening to live music provided by a therapist).

"This review increases our understanding of the effects of music therapy and strengthens the case for incorporating music in dementia care, particularly in care home settings.

“Music therapy offers benefits beyond those of other group activities, helping to support mood and behaviour in a way that is engaging and accessible, even in later stages of dementia. Care home managers should consider integrating structured musical sessions as part of a person-centred approach to dementia care.”

- Jenny van der Steen, lead author from Leiden University Medical Center and Radboudumc Alzheimer Center.

The findings suggest that music-based therapy probably improves depressive symptoms and may improve overall behavioural problems by the end of treatment. Music therapy is unlikely to significantly impact agitation, aggression, emotional well-being, or cognition but, when compared to other interventions, there is some evidence that it may improve social behaviour and could decrease anxiety. 

Long-term effects, beyond four weeks after treatment, may be smaller but remain uncertain due to the limited number of trials monitoring effects after treatment ends.

The review also highlights the growing recognition of non-pharmacological interventions in dementia care. 

“Music therapy is a drug-free way of helping people feel less sad and less anxious. We hope that the higher quality of recent studies and increasing evidence-base will result in more attention being given to music therapy and other non-pharmacological approaches.

"Looking at the effect sizes, music therapy is a reasonable alternative to pharmacological approaches and is much more person-centred.”

- Annemieke Vink, co-author from ArtEZ University of the Arts who has first-hand experience delivering music therapy to people with dementia.

The review underscores the need for further research into the long-term effects of music-based therapy particularly in community settings. Much of the existing evidence comes from care homes, so expanding studies to community-based environments could provide valuable insights into how music therapy can be integrated into everyday life for people living with dementia.

• Read the Cochrane review and the plain language summary
• Read the press release in Spanish

 

Wednesday, March 5, 2025

A new Cochrane review has found evidence that music-based therapy may benefit people living with dementia, particularly by improving symptoms of depression. 

Dementia is a collective term for progressive degenerative brain syndromes that affect memory, thinking, behaviour and emotion. Alzheimer’s Disease International reported that there were 55 million people with dementia worldwide in 2019, a figure predicted to increase to 139 million by 2050. While some medicines are available, the therapeutic use of music is considered a relatively simple and inexpensive approach that remains accessible even in the later stages of dementia.  

The research team from several institutions in the Netherlands examined evidence from 30 studies involving 1,720 people. The studies investigated the effects of music-based therapeutic interventions on emotional well-being including quality of life, mood disturbance, behavioural problems, social behaviour, and cognition. Most participants were in care homes, with interventions delivered either individually or in group settings. 

The trials were primarily conducted in high-income countries, including Australia, Taiwan, the US, and various European countries.  Almost all the therapies included active elements (such as playing instruments), often combined with receptive elements (such as listening to live music provided by a therapist).

"This review increases our understanding of the effects of music therapy and strengthens the case for incorporating music in dementia care, particularly in care home settings.

“Music therapy offers benefits beyond those of other group activities, helping to support mood and behaviour in a way that is engaging and accessible, even in later stages of dementia. Care home managers should consider integrating structured musical sessions as part of a person-centred approach to dementia care.”

- Jenny van der Steen, lead author from Leiden University Medical Center and Radboudumc Alzheimer Center.

The findings suggest that music-based therapy probably improves depressive symptoms and may improve overall behavioural problems by the end of treatment. Music therapy is unlikely to significantly impact agitation, aggression, emotional well-being, or cognition but, when compared to other interventions, there is some evidence that it may improve social behaviour and could decrease anxiety. 

Long-term effects, beyond four weeks after treatment, may be smaller but remain uncertain due to the limited number of trials monitoring effects after treatment ends.

The review also highlights the growing recognition of non-pharmacological interventions in dementia care. 

“Music therapy is a drug-free way of helping people feel less sad and less anxious. We hope that the higher quality of recent studies and increasing evidence-base will result in more attention being given to music therapy and other non-pharmacological approaches.

"Looking at the effect sizes, music therapy is a reasonable alternative to pharmacological approaches and is much more person-centred.”

- Annemieke Vink, co-author from ArtEZ University of the Arts who has first-hand experience delivering music therapy to people with dementia.

The review underscores the need for further research into the long-term effects of music-based therapy particularly in community settings. Much of the existing evidence comes from care homes, so expanding studies to community-based environments could provide valuable insights into how music therapy can be integrated into everyday life for people living with dementia.

• Read the Cochrane review and the plain language summary
• Read the press release in Spanish

 

Wednesday, March 5, 2025

Title:  Systematic Reviewer
Specifications: Permanent – Part time (0.6 FTE)
Salary: £45,000 per annum (£27,000 per annum at 0.6 FTE)
Location: (Remote) resident in the UK, Germany or Denmark. 
Directorate: Development and External Relations Directorate
Closing date: 17 March, 2025

As a Systematic Reviewer you will assist with the provision and delivery of commissioned systematic reviews and review tasks for Cochrane Response, Cochrane’s evidence consultancy unit.

Cochrane Response provides a broad range of literature review and evidence synthesis services to international policy makers and guideline developers to support evidence informed healthcare decision making. We work closely with Cochrane networks to increase Cochrane’s capacity to respond to requests for commissioned evidence reviews and tailored evidence services.

This position is aligned with Cochrane’s strategy to secure the long-term sustainability of the organisation by ensuring the success of Cochrane Response as a business unit that produces relevant information to guide healthcare decisions and responds to the needs of our stakeholders.

Joining our team means becoming part of a mission to enhance global health through reliable, evidence-based practices. You'll collaborate with dedicated professionals and partners worldwide to ensure health decisions are informed by the best available data. Our core values — collaboration, relevance, integrity, and quality — guide all our actions. By joining us, you'll contribute to making a significant impact on health outcomes globally.

Don’t have every single qualification? We know that some people are less likely to apply for a job unless they are a perfect match. At Cochrane, we’re not looking for “perfect matches.” We’re looking to welcome people to our diverse, inclusive, and passionate workplace. So, if you’re excited about this role but don’t have every single qualification, we encourage you to apply anyway. Whether it’s this role or another one, you may be just the right candidate.

Cochrane welcomes applications from a wide range of perspectives, experiences, locations and backgrounds; diversity, equity and inclusion are key to our values.

How to apply

• For further information on the role and how to apply, please click here.
• The deadline to receive your application is 17th March, 2025.  We reserve the right to close this vacancy early if we receive sufficient applications for the role. Therefore, if you are interested, please submit your application as early as possible.
• The supporting statement should indicate why you are applying for the post, and how far you meet the requirements, using specific examples.
• Interviews will be held on w/c 24th March 2025.
• Read our Recruitment Privacy Statement.
• Read our Candidate pack for more information on the hiring process and staff benefits.

 

Tuesday, March 4, 2025 Category: Jobs

Title:  Systematic Reviewer
Specifications: Permanent – Part time (0.6 FTE)
Salary: £45,000 per annum (£27,000 per annum at 0.6 FTE)
Location: (Remote) resident in the UK, Germany or Denmark. 
Directorate: Development and External Relations Directorate
Closing date: 17 March, 2025

As a Systematic Reviewer you will assist with the provision and delivery of commissioned systematic reviews and review tasks for Cochrane Response, Cochrane’s evidence consultancy unit.

Cochrane Response provides a broad range of literature review and evidence synthesis services to international policy makers and guideline developers to support evidence informed healthcare decision making. We work closely with Cochrane networks to increase Cochrane’s capacity to respond to requests for commissioned evidence reviews and tailored evidence services.

This position is aligned with Cochrane’s strategy to secure the long-term sustainability of the organisation by ensuring the success of Cochrane Response as a business unit that produces relevant information to guide healthcare decisions and responds to the needs of our stakeholders.

Joining our team means becoming part of a mission to enhance global health through reliable, evidence-based practices. You'll collaborate with dedicated professionals and partners worldwide to ensure health decisions are informed by the best available data. Our core values — collaboration, relevance, integrity, and quality — guide all our actions. By joining us, you'll contribute to making a significant impact on health outcomes globally.

Don’t have every single qualification? We know that some people are less likely to apply for a job unless they are a perfect match. At Cochrane, we’re not looking for “perfect matches.” We’re looking to welcome people to our diverse, inclusive, and passionate workplace. So, if you’re excited about this role but don’t have every single qualification, we encourage you to apply anyway. Whether it’s this role or another one, you may be just the right candidate.

Cochrane welcomes applications from a wide range of perspectives, experiences, locations and backgrounds; diversity, equity and inclusion are key to our values.

How to apply

• For further information on the role and how to apply, please click here.
• The deadline to receive your application is 17th March, 2025.  We reserve the right to close this vacancy early if we receive sufficient applications for the role. Therefore, if you are interested, please submit your application as early as possible.
• The supporting statement should indicate why you are applying for the post, and how far you meet the requirements, using specific examples.
• Interviews will be held on w/c 24th March 2025.
• Read our Recruitment Privacy Statement.
• Read our Candidate pack for more information on the hiring process and staff benefits.

 

Tuesday, March 4, 2025 Category: Jobs

We are delighted to announce a new, joint Methods Group between the Cochrane Collaboration, the Campbell Collaboration, JBI and the Collaboration for Environmental Evidence (CEE) focusing on artificial intelligence (AI) and automation in evidence synthesis. 

The rapidly growing evidence base and the increasing complexity of methods makes completing timely, high-quality, and comprehensive evidence synthesis, more and more challenging. Artificial intelligence (AI) and automation promises to help address this, and make it possible to keep up with the demand and expectations of users of evidence synthesis. But to realize this potential, we - as a collective across the whole evidence synthesis ecosystem - need to ensure AI doesn’t compromise on the principles of research integrity in which evidence synthesis was built. Therefore, this Methods Group will help define and support responsible AI use across four of the leading evidence synthesis organizations, including the Cochrane Collaboration, the Campbell Collaboration, JBI and the Collaboration for Environmental Evidence (CEE).   

As a Methods Group, we aim to: 

• Spearhead methods research and development and act as a bridge between evidence synthesis organizations and the wider research community. 
• Define best practice and ensure guidance for accepted methods is up to date. 
• Support the implementation of new or amended methods by acting as an advisor or through involvement in methods implementation in our respective evidence synthesis organizations.  

Spearheading methods research and development and act as a bridge between evidence synthesis organizations and the wider research community. 

We are part of the International Collaboration for Automation in Systematic Reviews (ICASR) and recommend those who want to share and discuss AI methods research, developments and opportunities, do so via the ICASR LinkedIn group, as we will as a Methods Group. 

Across our Methods Group, we are also involved in other key developments in the evidence synthesis ecosystem, including the Evidence Synthesis Infrastructure Collaborative safe and responsible use of AI working group. 

Our aim is for the Methods Group to work across these organizations and developments in the field and facilitate discussion and critical thinking, particularly around standards for accuracy, evaluations and validation, with events, webinars and other activities.  

Defining best practice and ensuring guidance for accepted methods is up to date. 

We are involved the responsible AI use in evidence synthesis recommendations and guidance (RAISE), which offers tailored advice for a diverse range of roles in the evidence synthesis ecosystem. Whether you're an evidence synthesist, methodologist, AI developer, or an organization or publisher involved in evidence synthesis, this guidance is a first step to help clarify your responsibilities and alleviate some of the concerns around AI use. For more information see the RAISE Open Science Framework project page. 

One of our first actions as a Methods Group will be to  provisionally endorse the next version of the RAISE recommendations and guidance for use in Cochrane, the Campbell Collaboration, JBI and the Collaboration for Environmental Evidence (CEE), which  is due to be released soon. 

Supporting the implementation of new or amended methods by acting as an advisor or through involvement in the methods implementation projects.  

The Methods Group has individuals from across four of the major evidence synthesis organizations, and even though implementation of AI and automation is the responsibility of each organization individually, by coming together we can aim to align best practice and share lessons learned on effective approaches. Our implementation will be based on the RAISE recommendations, with more details being shared in the coming months.  

As a first step, we are in the process of defining our position on AI and automation for researchers and authors within our organizations, to ensure they have clarity and are empowered to use them in their evidence synthesis. 

Our implementation will also consider how we can we improve AI literacy across our organizations, including how we can work with methodologists and trainers, so researchers and editors have the skills they need to ensure AI is used responsibly and reported transparently.  

 

Methods Group Convenors: 

• Ella Flemyng (Cochrane, UK)
• Gerald Gartlehner (University for Continuing Education Krems and Cochrane Austria, Austria)
• Zoe Jordan (JBI, Australia)
• Biljana Macura (Stockholm Environmental Institute and the Collaboration for Environmental Evidence, Sweden)
• Joerg Meerpohl (University of Freiburg and Cochrane Germany, Germany)
• Will Moy (Campbell, UK)
• Anna Noel Storr (Cochrane, UK)
• James Thomas (UCL, UK) 

Want to find out more? 

Register for the webinar on ‘Recommendations and guidance on responsible AI in evidence synthesis’ on 3 June 2025, part of the Artificial Intelligence (AI) methods in evidence synthesis series, to find out about why we all need to embrace responsible AI and how this Methods Group will support it. 

Also see our AI Methods Group website, which includes a news and events section. You can also follow each individual organization for more news and information as the Group develops. 

 

 

Friday, February 28, 2025

We are delighted to announce a new, joint Methods Group between the Cochrane Collaboration, the Campbell Collaboration, JBI and the Collaboration for Environmental Evidence (CEE) focusing on artificial intelligence (AI) and automation in evidence synthesis. 

The rapidly growing evidence base and the increasing complexity of methods makes completing timely, high-quality, and comprehensive evidence synthesis, more and more challenging. Artificial intelligence (AI) and automation promises to help address this, and make it possible to keep up with the demand and expectations of users of evidence synthesis. But to realize this potential, we - as a collective across the whole evidence synthesis ecosystem - need to ensure AI doesn’t compromise on the principles of research integrity in which evidence synthesis was built. Therefore, this Methods Group will help define and support responsible AI use across four of the leading evidence synthesis organizations, including the Cochrane Collaboration, the Campbell Collaboration, JBI and the Collaboration for Environmental Evidence (CEE).   

As a Methods Group, we aim to: 

• Spearhead methods research and development and act as a bridge between evidence synthesis organizations and the wider research community. 
• Define best practice and ensure guidance for accepted methods is up to date. 
• Support the implementation of new or amended methods by acting as an advisor or through involvement in methods implementation in our respective evidence synthesis organizations.  

Spearheading methods research and development and act as a bridge between evidence synthesis organizations and the wider research community. 

We are part of the International Collaboration for Automation in Systematic Reviews (ICASR) and recommend those who want to share and discuss AI methods research, developments and opportunities, do so via the ICASR LinkedIn group, as we will as a Methods Group. 

Across our Methods Group, we are also involved in other key developments in the evidence synthesis ecosystem, including the Evidence Synthesis Infrastructure Collaborative safe and responsible use of AI working group. 

Our aim is for the Methods Group to work across these organizations and developments in the field and facilitate discussion and critical thinking, particularly around standards for accuracy, evaluations and validation, with events, webinars and other activities.  

Defining best practice and ensuring guidance for accepted methods is up to date. 

We are involved the responsible AI use in evidence synthesis recommendations and guidance (RAISE), which offers tailored advice for a diverse range of roles in the evidence synthesis ecosystem. Whether you're an evidence synthesist, methodologist, AI developer, or an organization or publisher involved in evidence synthesis, this guidance is a first step to help clarify your responsibilities and alleviate some of the concerns around AI use. For more information see the RAISE Open Science Framework project page. 

One of our first actions as a Methods Group will be to  provisionally endorse the next version of the RAISE recommendations and guidance for use in Cochrane, the Campbell Collaboration, JBI and the Collaboration for Environmental Evidence (CEE), which  is due to be released soon. 

Supporting the implementation of new or amended methods by acting as an advisor or through involvement in the methods implementation projects.  

The Methods Group has individuals from across four of the major evidence synthesis organizations, and even though implementation of AI and automation is the responsibility of each organization individually, by coming together we can aim to align best practice and share lessons learned on effective approaches. Our implementation will be based on the RAISE recommendations, with more details being shared in the coming months.  

As a first step, we are in the process of defining our position on AI and automation for researchers and authors within our organizations, to ensure they have clarity and are empowered to use them in their evidence synthesis. 

Our implementation will also consider how we can we improve AI literacy across our organizations, including how we can work with methodologists and trainers, so researchers and editors have the skills they need to ensure AI is used responsibly and reported transparently.  

 

Methods Group Convenors: 

• Ella Flemyng (Cochrane, UK)
• Gerald Gartlehner (University for Continuing Education Krems and Cochrane Austria, Austria)
• Zoe Jordan (JBI, Australia)
• Biljana Macura (Stockholm Environmental Institute and the Collaboration for Environmental Evidence, Sweden)
• Joerg Meerpohl (University of Freiburg and Cochrane Germany, Germany)
• Will Moy (Campbell, UK)
• Anna Noel Storr (Cochrane, UK)
• James Thomas (UCL, UK) 

Want to find out more? 

Register for the webinar on ‘Recommendations and guidance on responsible AI in evidence synthesis’ on 3 June 2025, part of the Artificial Intelligence (AI) methods in evidence synthesis series, to find out about why we all need to embrace responsible AI and how this Methods Group will support it. 

Also see our AI Methods Group website, which includes a news and events section. You can also follow each individual organization for more news and information as the Group develops. 

 

 

Friday, February 28, 2025

Title:  Head of Publishing Operations 
Specifications: Permanent – Full Time 
Salary: £63,000 per annum 
Location: (Remote) resident in the UK, Germany or Denmark.  
Directorate: Publishing and Technology Directorate 
Closing date: 14 March, 2025 

We are seeking an experienced and proactive Head of Publishing Operations to lead and manage Cochrane’s publishing systems and processes. In this key role, you will act as liaison between internal teams, external technology suppliers, and our publishing partner, ensuring smooth, efficient and innovative xml-first workflows from submission to publication. You will oversee the performance of our publishing technology, manage vendor relationships, and drive continuous improvements to our production processes. With a strong focus on operational excellence, stakeholder collaboration, and author experience, you will play a pivotal role in ensuring Cochrane’s publishing systems and processes are efficient, reliable, and aligned with our strategic goals. 

Joining our team means becoming part of a mission to enhance global health through reliable, evidence-based practices. You'll collaborate with dedicated professionals and partners worldwide to ensure health decisions are informed by the best available data. Our core values — collaboration, relevance, integrity, and quality — guide all our actions. By joining us, you'll contribute to making a significant impact on health outcomes globally. 

Don’t have every single qualification? We know that some people are less likely to apply for a job unless they are a perfect match. At Cochrane, we’re not looking for “perfect matches.” We’re looking to welcome people to our diverse, inclusive, and passionate workplace. So, if you’re excited about this role but don’t have every single qualification, we encourage you to apply anyway. Whether it’s this role or another one, you may be just the right candidate. 

Cochrane welcomes applications from a wide range of perspectives, experiences, locations and backgrounds; diversity, equity and inclusion are key to our values. 

How to apply 

• For further information on the role and how to apply, please click here. 
• The deadline to receive your application is 14th March, 2025.  We reserve the right to close this vacancy early if we receive sufficient applications for the role. Therefore, if you are interested, please submit your application as early as possible. 
• The supporting statement should indicate why you are applying for the post, and how far you meet the requirements, using specific examples. 
• Interviews will be held on w/c 24th March, 2025.
• Read our Recruitment Privacy Statement
• Read our Candidate pack for more information on the hiring process and staff benefits 

Friday, February 28, 2025 Category: Jobs

Title:  Head of Publishing Operations 
Specifications: Permanent – Full Time 
Salary: £63,000 per annum 
Location: (Remote) resident in the UK, Germany or Denmark.  
Directorate: Publishing and Technology Directorate 
Closing date: 14 March, 2025 

We are seeking an experienced and proactive Head of Publishing Operations to lead and manage Cochrane’s publishing systems and processes. In this key role, you will act as liaison between internal teams, external technology suppliers, and our publishing partner, ensuring smooth, efficient and innovative xml-first workflows from submission to publication. You will oversee the performance of our publishing technology, manage vendor relationships, and drive continuous improvements to our production processes. With a strong focus on operational excellence, stakeholder collaboration, and author experience, you will play a pivotal role in ensuring Cochrane’s publishing systems and processes are efficient, reliable, and aligned with our strategic goals. 

Joining our team means becoming part of a mission to enhance global health through reliable, evidence-based practices. You'll collaborate with dedicated professionals and partners worldwide to ensure health decisions are informed by the best available data. Our core values — collaboration, relevance, integrity, and quality — guide all our actions. By joining us, you'll contribute to making a significant impact on health outcomes globally. 

Don’t have every single qualification? We know that some people are less likely to apply for a job unless they are a perfect match. At Cochrane, we’re not looking for “perfect matches.” We’re looking to welcome people to our diverse, inclusive, and passionate workplace. So, if you’re excited about this role but don’t have every single qualification, we encourage you to apply anyway. Whether it’s this role or another one, you may be just the right candidate. 

Cochrane welcomes applications from a wide range of perspectives, experiences, locations and backgrounds; diversity, equity and inclusion are key to our values. 

How to apply 

• For further information on the role and how to apply, please click here. 
• The deadline to receive your application is 14th March, 2025.  We reserve the right to close this vacancy early if we receive sufficient applications for the role. Therefore, if you are interested, please submit your application as early as possible. 
• The supporting statement should indicate why you are applying for the post, and how far you meet the requirements, using specific examples. 
• Interviews will be held on w/c 24th March, 2025.
• Read our Recruitment Privacy Statement
• Read our Candidate pack for more information on the hiring process and staff benefits 

Friday, February 28, 2025 Category: Jobs